In recent years biotech executives have felt pressure from their investors and handlers to tone down talk of the firm's new technology because it sends the message that the company isn't sufficiently product focused. This is rubbish!
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Rights and permissions
About this article
Cite this article
Silverman, E. Who took the tech out of biotech?. Nat Biotechnol 24, 255–256 (2006). https://doi.org/10.1038/nbt0306-255
Issue Date:
DOI: https://doi.org/10.1038/nbt0306-255